DGIdb - INDINAVIR Drug Record

INDINAVIR chembl:CHEMBL115 Approved

Alternate Names:

CRIXIVAN
L-735524
INDINAVIR
INDINAVIR SYSTEM SUITABILITY
INDINAVIR MONOHYDRATE
MK-639
INDINAVIR ANHYDROUS
(1(1S,2R),5(S))-2,3,5-TRIDEOXY-N-(2,3-DIHYDRO-2-HYDROXY-1H-INDEN-1-YL)-5-(2-(((1,1-DIMETHYLETHYL)AMINO)CARBONYL)-4-(3-PYRIDINYLMETHYL)-1-PIPERAZINYL)-2-(PHENYLMETHYL)-D-ERYTHRO-PENTONAMIDE
chemidplus:150378-17-9
pubchem.compound:5362440
rxcui:1546024
rxcui:114289
chembl:CHEMBL115
drugbank:00224

Drug Info:

(1 More Sources)

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
Skowron et al., 1999, The safety and efficacy of granulocyte-macrophage colony-stimulating factor (Sargramostim) added to indinavir- or ritonavir-based antiretroviral therapy: a randomized double-blind, placebo-controlled trial., J. Infect. Dis.
Lenhard et al., 2000, HIV protease inhibitors block adipogenesis and increase lipolysis in vitro., Antiviral Res.
Maruo Y et al., 1999, Association of neonatal hyperbilirubinemia with bilirubin UDP-glucuronosyltransferase polymorphism., Pediatrics
Akaba K et al., 1998, Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese., Biochem Mol Biol Int
Yamamoto K et al., 1998, Contribution of two missense mutations (G71R and Y486D) of the bilirubin UDP glycosyltransferase (UGT1A1) gene to phenotypes of Gilbert's syndrome and Crigler-Najjar syndrome type II., Biochim Biophys Acta
Bosma PJ et al., 1995, The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome., N Engl J Med
Turatti L et al., 2012, Short communication: UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in southern Brazil., AIDS Res Hum Retroviruses
Hu ZY et al., 2010, Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk., Clin Cancer Res
Park WB et al., 2010, Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency., Clin Infect Dis
Hu ZY et al., 2010, Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis., Eur J Cancer
Onoue M et al., 2009, UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients., Int J Clin Oncol
Takano M et al., 2009, Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study., Oncology
Hoskins JM et al., 2007, UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters., J Natl Cancer Inst
Jada SR et al., 2007, Role of UGT1A16, UGT1A128 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients., Cancer Sci
Lankisch TO et al., 2006, Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype., Hepatology
Urawa N et al., 2006, Linkage disequilibrium of UGT1A1 6 and UGT1A1 28 in relation to UGT1A6 and UGT1A7 polymorphisms., Oncol Rep
Toffoli G et al., 2006, The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer., J Clin Oncol
Boyd MA et al., 2006, Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir., Pharmacogenet Genomics
Massacesi et al., 2006, Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy., Cancer
Rotger M et al., 2005, Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia., J Infect Dis
Zhang D et al., 2005, In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation., Drug Metab Dispos
Carlini et al., 2005, UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan., Clin. Cancer Res.
Rouits E et al., 2004, Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients., Clin Cancer Res
Innocenti F et al., 2004, Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan., J Clin Oncol
Tukey RH et al., 2002, Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity., Mol Pharmacol
Ando Y et al., 2000, Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis., Cancer Res
Hall D et al., 1999, Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates., Pharmacogenetics
Hruz et al., 2002, Indinavir induces acute and reversible peripheral insulin resistance in rats., Diabetes

INDINAVIR UGT1A1

Interaction Score: 4.34

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10353933 9784835 9630669 7565971 22050734 20562211 20504240 20335017 19390945 19299905 17728214 17627617 17058217 16969497 16809730 16609363 16456808 16170755 16118329 15709193 15297419 15007088 12181419 11156391 10591539

Sources:
PharmGKB
INDINAVIR TFAP2A

Interaction Score: 4.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10996400

Sources:
NCI
INDINAVIR CSF2

Interaction Score: 0.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10479132

Sources:
NCI
INDINAVIR SLC2A4

Interaction Score: 0.28

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11916910

Sources:
NCI
INDINAVIR CYP2C9

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
INDINAVIR CYP3A4

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9187528 22931300

Sources:
DTC PharmGKB
INDINAVIR CYP2C19

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
INDINAVIR ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
INDINAVIR CYP1A2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
INDINAVIR CYP2D6

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC

NCI: INDINAVIR

Version: 14-September-2017

Alternate Names:

C1662 NCI drug code

Drug Info:

Publications:

Lenhard et al., 2000, HIV protease inhibitors block adipogenesis and increase lipolysis in vitro., Antiviral Res.

Hruz et al., 2002, Indinavir induces acute and reversible peripheral insulin resistance in rats., Diabetes

Skowron et al., 1999, The safety and efficacy of granulocyte-macrophage colony-stimulating factor (Sargramostim) added to indinavir- or ritonavir-based antiretroviral therapy: a randomized double-blind, placebo-controlled trial., J. Infect. Dis.

DTC: INDINAVIR
- Version: 02-September-2020
Alternate Names:

CHEMBL115 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

PharmGKB: indinavir

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Maruo Y et al., 1999, Association of neonatal hyperbilirubinemia with bilirubin UDP-glucuronosyltransferase polymorphism., Pediatrics

Bosma PJ et al., 1995, The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome., N Engl J Med

Jada SR et al., 2007, Role of UGT1A16, UGT1A128 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients., Cancer Sci

TTD: Indinavir
- Version: 2020.06.01
Alternate Names:

D0V7CF TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL115
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

INDINAVIR Drug Record

INDINAVIR chembl:CHEMBL115 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10353933 9784835 9630669 7565971 22050734 20562211 20504240 20335017 19390945 19299905 17728214 17627617 17058217 16969497 16809730 16609363 16456808 16170755 16118329 15709193 15297419 15007088 12181419 11156391 10591539

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10996400

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10479132

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11916910

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9187528 22931300

Sources: DTC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

NCI: INDINAVIR

Alternate Names: C1662 NCI drug code

Drug Info:

DTC: INDINAVIR

Alternate Names: CHEMBL115 ChEMBL Drug ID

Drug Info:

Publications: Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for &gt;200 compounds., Chem Res Toxicol

PharmGKB: indinavir

Alternate Names:

Drug Info:

TTD: Indinavir

Alternate Names: D0V7CF TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL115

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

PMIDs:
10353933 9784835 9630669 7565971 22050734 20562211 20504240 20335017 19390945 19299905 17728214 17627617 17058217 16969497 16809730 16609363 16456808 16170755 16118329 15709193 15297419 15007088 12181419 11156391 10591539

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
10996400

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
10479132

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
11916910

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
9187528 22931300

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Alternate Names:

C1662 NCI drug code

Alternate Names:

CHEMBL115 ChEMBL Drug ID

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Alternate Names:

D0V7CF TTD Drug ID